WHO ICTRP trial
treatment outcomes of dienogest versus elagolix in endometriosis
CTRI/2026/01/101119 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2026/01/101119 |
|---|---|
| Public title | treatment outcomes of dienogest versus elagolix in endometriosis |
| Scientific title | Comparative Effectiveness of Dienogest and Elagolix in Endometriosis: A Prospective Observational Study at a Tertiary Care Centre in Northern India - NIL |
| Primary sponsor | University of Kashmir |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Post Marketing Surveillance |
| Countries | India |
| Conditions | Health Condition 1: N00-N99- Diseases of the genitourinary system |
| Interventions | Intervention1: Elagolix: dose 150 mg once a day orally for three months Intervention2: Elagolix 150 mg once day: Nil Intervention3: Nil: Nil Control Intervention1: Dienogest: Dose 2 mg once a day orally for three months |
| Registration date | Jan 14, 2026 |
| Target size | 200 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: